HRP20191711T1 - Oftalmološki pripravak - Google Patents
Oftalmološki pripravak Download PDFInfo
- Publication number
- HRP20191711T1 HRP20191711T1 HRP20191711T HRP20191711T1 HR P20191711 T1 HRP20191711 T1 HR P20191711T1 HR P20191711 T HRP20191711 T HR P20191711T HR P20191711 T1 HRP20191711 T1 HR P20191711T1
- Authority
- HR
- Croatia
- Prior art keywords
- ophthalmic preparation
- preparation according
- ophthalmic
- eye
- fatty acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (16)
1. Oftalmološki pripravak koji sadrži disperziju poliafrona,
pri čemu disperzija poliafrona sadrži barem jedan neionski, nehalogenirani surfaktant.
2. Oftalmološki pripravak u skladu s patentnim zahtjevom 1 u obliku tekućine, i/ili u obliku kapi za oči.
3. Oftalmološki pripravak u skladu s patentnim zahtjevima 1 ili 2 koji sadrži farmaceutski aktivnu tvar, poželjno pri čemu je farmaceutski aktivna tvar odabrana iz grupe koja se sastoji od antihistaminika, beta blokatora, kortikosteroida, prostaglandina, nesteroidnih protuupalnih lijekova (NSAR), imunološkog modulatora, anestetika, antibiotika, inhibitora ugljične anhidraze, vazokonstriktora, i smjesa dviju ili više navedenih tvari.
4. Oftalmološki pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu farmaceutski aktivna tvar sadrži ciklosporin.
5. Oftalmološki pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu pripravak ima osmolalnost od 200 do 600 mOsm/kg.
6. Oftalmološki pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, koji sadrži sredstvo za toničnost, poželjno odabran između šećera, šećernog alkohola, glikola, karbamida i smjesa dviju ili više navedenih tvari.
7. Oftalmološki pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva koji sadrži omega-3 masnu kiselinu.
8. Oftalmološki pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu je pripravak pH vrijednosti od 3,5 do 9, poželjno od 5 do 8, a još poželjnije od 6 do 7,5.
9. Oftalmološki pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, koji sadrži sredstvo za geliranje i/ili viskoznosti je od 1 do 50 Pas pri brzini smicanja 1s-1.
10. Oftalmološki pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva koji sadrži farmaceutski prihvatljivo ulje odabrano iz skupine koja se sastoji od ricinusovog ulja, triglicerida dugog lanca, triglicerida srednjeg lanca, mineralnog ulja, silikona, fosfolipida, mono- i diglicerida i smjesa dviju ili više navedenih tvari; i/ili pri čemu je barem jedan neionski, nehalogenirani surfaktant odabran iz skupine koja se sastoji od polietilen glikol sorbitan estera masne kiselina, sorbitan estera masne kiseline, polietilen glikol estera masne kiseline, polietilen glikol stearat estera, polioksietilen glikol – blok – polipropilen glikol – blok – polioksietilen glikol – blok-a, polietilen glikol lauril estera i smjesa dviju ili više navedenih tvari.
11. Oftalmološki pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva u obliku gela za nanošenje na oko.
12. Oftalmološki pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu je srednji promjer kapljica afrona od 0,5 do 50 µm.
13. Oftalmološki pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva za uporabu u liječenju ljudskog i/ili životinjskog oka topikalnom primjenom.
14. Oftalmološki pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 12 za uporabu u liječenju ljudskog i/ili životinjskog oka topikalnom primjenom, pri čemu je pripravak primijenjen izravno na površinu oka.
15. Postupak izrade oftalmološkog pripravka u skladu s bilo kojim od prethodnih patentnih zahtjeva koji uključuje sljedeće korake:
(i) dobivanje hidrofilnog otapala;
(ii) dobivanje hidrofobnog otapala;
(iii) miješanje hidrofilnog otapala s hidrofobnim otapalom u prikladnim uvjetima kako bi se dobio pripravak koji sadrži poliafronsku disperziju;
pri čemu hidrofilno otapalo i/ili hidrofobno otapalo sadrži surfaktant;
i pri čemu hidrofilno otapalo i/ili hidrofobno otapalo opcionalno sadrži farmaceutski aktivnu tvar.
16. Postupak u skladu s patentnim zahtjevom 15 koji se provodi u sterilnim i/ili aseptičkim uvjetima; i/ili koji nadalje sadrži autoklaviranje oftalmološkog pripravka.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11158099 | 2011-03-14 | ||
| PCT/EP2012/054498 WO2012123515A1 (en) | 2011-03-14 | 2012-03-14 | An ophthalmic composition |
| EP12708358.2A EP2686017B1 (en) | 2011-03-14 | 2012-03-14 | An ophthalmic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191711T1 true HRP20191711T1 (hr) | 2019-12-13 |
Family
ID=44483953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191711 HRP20191711T1 (hr) | 2011-03-14 | 2012-03-14 | Oftalmološki pripravak |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9610245B2 (hr) |
| EP (1) | EP2686017B1 (hr) |
| JP (1) | JP6105494B2 (hr) |
| CN (2) | CN108273065B (hr) |
| AU (1) | AU2012228273B2 (hr) |
| BR (1) | BR112013023458B1 (hr) |
| CA (1) | CA2829164C (hr) |
| DK (1) | DK2686017T3 (hr) |
| ES (1) | ES2736256T3 (hr) |
| HR (1) | HRP20191711T1 (hr) |
| HU (1) | HUE045467T2 (hr) |
| PL (1) | PL2686017T3 (hr) |
| PT (1) | PT2686017T (hr) |
| RU (1) | RU2639472C2 (hr) |
| SI (1) | SI2686017T1 (hr) |
| WO (1) | WO2012123515A1 (hr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6417168B1 (en) | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
| US10265265B2 (en) | 2007-03-15 | 2019-04-23 | Drug Delivery Solutions Limited | Topical composition |
| HRP20191711T1 (hr) | 2011-03-14 | 2019-12-13 | Drug Delivery Solutions Ltd | Oftalmološki pripravak |
| US11116769B2 (en) * | 2013-04-11 | 2021-09-14 | Ctc Bio, Inc. | Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer |
| GB201410869D0 (en) * | 2014-06-18 | 2014-07-30 | Perioc Ltd | Novel pharmaceutical formulations and their use in the treatment of periodontal disease |
| US20200237859A1 (en) | 2019-01-25 | 2020-07-30 | Newport Research, Inc. | Aqueous suspensions of cyclosporin |
| US11324800B2 (en) | 2015-01-15 | 2022-05-10 | Wellspring Ophthalmics, Inc. | Aqueous suspensions of cyclosporin |
| KR102638112B1 (ko) * | 2015-02-02 | 2024-02-20 | 산텐 세이야꾸 가부시키가이샤 | 폴리아프론 및 이의 안검 투여 |
| EP4417259A3 (en) | 2015-09-11 | 2024-10-23 | The Schepens Eye Research Institute, Inc. | Compositions and methods for prevention and treatment of corneal haze and scarring |
| US10286035B2 (en) | 2015-10-14 | 2019-05-14 | Paul Gavaris | Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents |
| LT3266446T (lt) * | 2016-07-07 | 2019-01-25 | Laboratorios Salvat, S.A. | Oftalmologinė kompozicija, apimanti ricinos aliejų ir vidutinio grandinės ilgio trigliceridą |
| EP3542788A1 (en) | 2018-03-19 | 2019-09-25 | MC2 Therapeutics Limited | Topical composition comprising calcipotriol and betamethasone dipropionate |
| CN108578617B (zh) * | 2018-04-09 | 2021-03-30 | 深圳市莱利赛生物科技有限公司 | 促进膝关节软骨再生用脐血间质干细胞药物的制备方法 |
| EP3807404A1 (en) | 2018-06-13 | 2021-04-21 | Voyager Therapeutics, Inc. | Engineered 5' untranslated regions (5' utr) for aav production |
| MX2021000810A (es) | 2018-07-24 | 2021-04-28 | Voyager Therapeutics Inc | Sistemas y metodos para producir formulaciones de terapia genetica. |
| TW202035689A (zh) | 2018-10-04 | 2020-10-01 | 美商航海家醫療公司 | 測量病毒載體粒子的效價及強度之方法 |
| SG11202103425YA (en) | 2018-10-05 | 2021-05-28 | Voyager Therapeutics Inc | Engineered nucleic acid constructs encoding aav production proteins |
| TW202028468A (zh) | 2018-10-15 | 2020-08-01 | 美商航海家醫療公司 | 用於桿狀病毒/Sf9系統中rAAV之大規模生產的表現載體 |
| JP2022522995A (ja) | 2019-01-18 | 2022-04-21 | ボイジャー セラピューティクス インコーポレイテッド | Ａａｖ粒子を生成するための方法及びシステム |
| TW202106879A (zh) | 2019-04-29 | 2021-02-16 | 美商航海家醫療公司 | 於生物反應器中生產經桿狀病毒感染之昆蟲細胞(biic)之系統及方法 |
| WO2021030125A1 (en) | 2019-08-09 | 2021-02-18 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| EP4022070A1 (en) | 2019-08-26 | 2022-07-06 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2022032153A1 (en) | 2020-08-06 | 2022-02-10 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| WO2022187548A1 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| US20240141377A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| CA3211874A1 (en) * | 2021-03-16 | 2022-09-22 | Kumaresh Soppimath | Multi-dose container for ophthalmic compositions |
| TW202412751A (zh) * | 2022-08-09 | 2024-04-01 | 日商參天製藥股份有限公司 | 含有udca或其鹽之水性醫藥組合物 |
| WO2024054983A1 (en) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS557228A (en) * | 1978-06-29 | 1980-01-19 | Lion Corp | Enzyme preparation |
| US4486333A (en) | 1981-04-10 | 1984-12-04 | Felix Sebba | Preparation of biliquid foam compositions |
| JPS59222409A (ja) | 1983-06-01 | 1984-12-14 | Nippon Redarii Kk | 消炎鎮痛ゲル軟膏剤 |
| CA1272953A (en) | 1984-10-08 | 1990-08-21 | Yuji Makino | Pharmaceutical composition for external use containing active-type vitamin d.sub.3 |
| JPH07553B2 (ja) | 1985-12-09 | 1995-01-11 | 佐藤製薬株式会社 | フイルム状製剤 |
| ZA888819B (en) | 1987-12-02 | 1990-07-25 | Ici Australia Operations | Process for preparing explosive |
| US4900552A (en) | 1988-03-30 | 1990-02-13 | Watson Laboratories, Inc. | Mucoadhesive buccal dosage forms |
| US4944938A (en) | 1988-12-16 | 1990-07-31 | Colgate-Palmolive Company | Antiperspirant and deodorant |
| US4999198A (en) | 1989-03-23 | 1991-03-12 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Polyaphrons as a drug delivery system |
| EP0474517B1 (en) | 1990-09-07 | 1998-11-18 | Wisconsin Alumni Research Foundation | Novel use of 1alpha-hydroxylated-19-nor-vitamin D compounds to treat psoriasis |
| US5840881A (en) | 1992-11-27 | 1998-11-24 | Takeda Chemical Industries, Ltd. | Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility |
| USRE39706E1 (en) | 1993-01-15 | 2007-06-26 | Leo Pharma A/S | Crystalline form of a vitamin D analogue |
| FR2710840B1 (fr) | 1993-10-04 | 1995-12-01 | Applic Transferts Technolo | Compositions viscoélastiques hautement concentrées en composés fluorés, leur préparation et leurs utilisations dans le domaine médical et en cosmétique. |
| GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| US6538039B2 (en) | 1994-04-29 | 2003-03-25 | Laboratoire L. Lafon | Pharmaceutical dosage form for transdermal administration |
| FR2719220A1 (fr) | 1994-04-29 | 1995-11-03 | Lafon Labor | Nouvelle forme galénique pour l'administration transdermique. |
| US5474979A (en) * | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
| IL110117A0 (en) | 1994-06-24 | 1994-10-07 | Univ Ben Gurion | Pharmaceutical compositions comprising vitamin-d analogs |
| KR0159145B1 (ko) | 1995-02-24 | 1998-12-01 | 강박광 | 피부 약물 전달 체계용 에멀젼 네트웍의 제조방법 |
| US6238678B1 (en) | 1995-11-06 | 2001-05-29 | The Procter & Gamble Company | Methods of regulating skin appearance with vitamin B3 compound |
| WO1997032559A1 (en) | 1996-03-08 | 1997-09-12 | Disperse Technologies Limited | Dispersions comprising an oil-based biliquid foam and an aqueous gel |
| US5660858A (en) | 1996-04-03 | 1997-08-26 | Research Triangle Pharmaceuticals | Cyclosporin emulsions |
| KR100471341B1 (ko) | 1996-05-23 | 2005-07-21 | 제네시스 테크놀로지 가부시키가이샤 | 콘택트프로브및그것을구비한프로브장치 |
| NL1003503C2 (nl) | 1996-07-04 | 1998-01-07 | Negma Steba International Dev | Farmaceutische samenstelling voor orale toediening. |
| US5800832A (en) | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
| US5955097A (en) | 1996-10-18 | 1999-09-21 | Virotex Corporation | Pharmaceutical preparation applicable to mucosal surfaces and body tissues |
| GB2326337A (en) | 1997-06-20 | 1998-12-23 | Phares Pharma Holland | Homogeneous lipid compositions for drug delivery |
| JP4761093B2 (ja) | 1997-12-10 | 2011-08-31 | シクロスポリン セラポイティクス リミテッド | オメガ−３脂肪酸油を含む医薬組成物 |
| US5990100A (en) | 1998-03-24 | 1999-11-23 | Panda Pharmaceuticals, L.L.C. | Composition and method for treatment of psoriasis |
| EP1079813B1 (en) | 1998-04-29 | 2005-02-09 | Virotex Corporation | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
| US8263580B2 (en) | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| SI3146969T1 (en) | 1999-04-23 | 2018-08-31 | Leo Pharma A/S | Ointment for topical treatment of psoriasis |
| US6200581B1 (en) | 1999-04-28 | 2001-03-13 | Dow Corning Corporation | Elastomeric silicone terpolymer |
| DE19938668B4 (de) * | 1999-08-14 | 2006-01-26 | Bausch & Lomb Inc. | Tränenersatzmittel |
| US6562370B2 (en) | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers |
| CN1362873A (zh) | 2000-02-22 | 2002-08-07 | 彩色通路公司 | 胶凝的水溶液美容组合物 |
| US6576712B2 (en) | 2000-07-07 | 2003-06-10 | A. V. Topchiev Institute Of Petrochemical Synthesis | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
| WO2002034235A1 (en) | 2000-10-27 | 2002-05-02 | Leo Pharma A/S | Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid |
| RU2276177C2 (ru) | 2001-05-01 | 2006-05-10 | Институт Нефтехимического Синтеза Имени А.В. Топчиева Российской Академии Наук | Получение гидрофильных, чувствительных к давлению адгезивов с оптимизированными адгезионными свойствами |
| WO2002096418A1 (en) | 2001-05-25 | 2002-12-05 | Valley Forge Pharmaceuticals | Pirenzepine ophthalmic gel |
| US6585997B2 (en) | 2001-08-16 | 2003-07-01 | Access Pharmaceuticals, Inc. | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| ATE397902T1 (de) | 2001-11-30 | 2008-07-15 | Koninkl Philips Electronics Nv | Bildverarbeitungsverfahren und system zum hervorheben von strukturen in verrauschten bildern |
| GB0202312D0 (en) | 2002-01-31 | 2002-03-20 | Disperse Technologies Plc | Polyaphron fuel compositions |
| GB0214793D0 (en) | 2002-06-26 | 2002-08-07 | Disperse Technologies Plc | Biliquid foam entrapment |
| US7820145B2 (en) * | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US7053124B2 (en) | 2002-11-06 | 2006-05-30 | Disperse Limited | Aerosol delivery systems |
| US20050026877A1 (en) | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| US20050020546A1 (en) | 2003-06-11 | 2005-01-27 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| WO2005001643A2 (en) | 2003-06-21 | 2005-01-06 | J Maev Jack Ivan | Method and apparatus for encouraged visitation web advertising |
| FR2856301B1 (fr) | 2003-06-23 | 2007-08-03 | Galderma Res & Dev | Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile |
| EP1648362A4 (en) | 2003-07-01 | 2012-01-11 | Todd Maibach | THERAPEUTIC AGENTS WITH FILM |
| GB0317869D0 (en) * | 2003-07-30 | 2003-09-03 | Disperse Ltd | Improved drug delivery system |
| GB0317868D0 (en) * | 2003-07-30 | 2003-09-03 | Disperse Ltd | Biliquid foams with a high alcohol content and products formulated therefrom |
| WO2005016321A1 (en) | 2003-08-15 | 2005-02-24 | Qlt Usa, Inc. | Adhesive bioerodible transmucosal drug delivery system |
| US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
| JP2005123083A (ja) | 2003-10-17 | 2005-05-12 | Dainippon Screen Mfg Co Ltd | 塗布組成物および有機ｅｌ素子の製造方法 |
| FR2862540B1 (fr) | 2003-11-21 | 2007-03-30 | Galderma Res & Dev | Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile |
| CA2543577A1 (en) | 2003-11-21 | 2005-06-16 | Galderma Research & Development, S.N.C. | Sprayable composition for the administration of vitamin d derivatives |
| GB0404403D0 (en) | 2004-02-27 | 2004-03-31 | Disperse Ltd | Dispersions |
| FR2871700B1 (fr) | 2004-06-17 | 2006-11-17 | Galderma Sa | Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, et une phase huileuse |
| FR2871699A1 (fr) | 2004-06-17 | 2005-12-23 | Galderma Sa | Composition de type emulsion inverse contenant du calcitrol et du 17-propionate de clobetasol, et ses utilisations en cosmetiques et en dermatologie |
| FR2871695B1 (fr) | 2004-06-17 | 2008-07-04 | Galderma Sa | Composition pharmaceutique comprenant un agent silicone et deux principes actifs solubilises |
| MXPA06014397A (es) | 2004-06-17 | 2007-02-15 | Galderma Sa | Composicion en forma de aerosol que comprende una combinacion de un corticoide y un derivado de la vitamina d en una fase aceitosa. |
| KR20070027587A (ko) | 2004-06-17 | 2007-03-09 | 갈데르마 소시에떼아노님 | 실리콘제, 코르티코스테로이드 및 비타민 ｄ 또는 이의유도체를 함유하는 건선 치료용 조성물 |
| FR2871698B1 (fr) | 2004-06-17 | 2008-07-04 | Galderma Sa | Composition sous forme de spray comprenant une association d'actifs pharmaceutiques et une phase huileuse |
| FR2871696B1 (fr) | 2004-06-17 | 2006-11-10 | Galderma Sa | Composition topique pour le traitement du psoriasis |
| DK1771180T4 (da) | 2004-06-17 | 2011-04-11 | Galderma Sa | Sammensætning i form af en spray, der omfatter en kombination af clobetasolpropionat og calcitriol, en alkoholfase og en oliefase |
| FR2871697B1 (fr) | 2004-06-17 | 2007-06-29 | Galderma Sa | Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, au moins un silicone volatile et une phase huileuse non volatile |
| FR2871694B1 (fr) | 2004-06-17 | 2008-07-04 | Galderma Sa | Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises |
| FR2871693B1 (fr) | 2004-06-17 | 2006-08-25 | Galderma Sa | Utilisation d'une composition pharmaceutique comprenant du calcitriol et du propionate de clobetasol pour le traitement du psoriasis |
| IT1333365B1 (it) | 2004-09-09 | 2006-04-11 | Alberto Fiorenzi | Apparecchiatura e procedimento per realizzare una vela e relativa vela realizzata |
| AU2005304034B2 (en) | 2004-11-09 | 2012-02-16 | Santen Sas | Ophthalmic emulsions containing an immunosuppressive agent |
| WO2006111426A1 (en) | 2005-04-19 | 2006-10-26 | Galderma S.A. | Composition of film-forming solution type, comprising vitamin d or a derivative thereof and a corticosteroid, and use thereof in dermatology |
| PL2526930T3 (pl) | 2005-06-01 | 2014-05-30 | Glaxosmithkline Ip Dev Ltd | Formulacja witaminowa |
| FR2889662B1 (fr) | 2005-08-11 | 2011-01-14 | Galderma Res & Dev | Emulsion de type huile-dans-eau pour application topique en dermatologie |
| US20070048369A1 (en) | 2005-08-26 | 2007-03-01 | National Starch And Chemical Investment Holding Corporation | Mucosal delivery tablet |
| US20070219127A1 (en) * | 2006-03-20 | 2007-09-20 | Walt John G | Cyclosporin a compositions |
| EP2079544A4 (en) | 2006-04-14 | 2012-09-05 | Nevada System Of Higher Education On Behalf Of The University Of Nevada Reno Board Of Regents | ARSENIC ABSORBENT COMPOSITION AND METHODS OF USE |
| ES2361635T3 (es) * | 2006-05-19 | 2011-06-20 | Scynexis, Inc. | Ciclosporinas para el tratamiento y prevención de trastornos oculares. |
| EP1970047A1 (en) * | 2007-03-15 | 2008-09-17 | Drug Delivery Solutions Limited | Polyaphron topical composition with a corticosteroid |
| EP1970048A1 (en) * | 2007-03-15 | 2008-09-17 | Drug Delivery Solutions Limited | Polyaphron topical composition with vitamin D |
| US10265265B2 (en) * | 2007-03-15 | 2019-04-23 | Drug Delivery Solutions Limited | Topical composition |
| EP1970049A1 (en) * | 2007-03-15 | 2008-09-17 | Drug Delivery Solutions Limited | Polyaphron topical composition with vitamin D and corticosteroid |
| EP2008651A1 (en) | 2007-06-26 | 2008-12-31 | Drug Delivery Solutions Limited | A bioerodible patch |
| GB0712389D0 (en) * | 2007-06-26 | 2007-08-01 | Drug Delivery Solutions Ltd | A Pharmaceutical composition |
| CA2730221C (en) | 2007-07-09 | 2016-02-02 | Novagali Pharma Sa | Oil in water emulsion comprising nsaids and quaternary ammonium halides |
| EP2564853B1 (en) | 2007-12-04 | 2019-02-27 | Santen SAS | Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders |
| US20110009339A1 (en) * | 2009-04-14 | 2011-01-13 | Allergan, Inc | Method of treating blurred vision and other conditions of the eye with cyclosporin compositions |
| US20100272875A1 (en) | 2009-04-24 | 2010-10-28 | Monsanto Technology Llc | Omega-3 enriched cereal, granola, and snack bars |
| US20100279951A1 (en) * | 2009-05-01 | 2010-11-04 | Aileen Morgan | Method of treating allergic conjunctivitis with cyclosporin compositions |
| US9480645B2 (en) * | 2009-06-02 | 2016-11-01 | Abbott Medical Optics Inc. | Omega-3 oil containing ophthalmic emulsions |
| HRP20191711T1 (hr) | 2011-03-14 | 2019-12-13 | Drug Delivery Solutions Ltd | Oftalmološki pripravak |
-
2012
- 2012-03-14 HR HRP20191711 patent/HRP20191711T1/hr unknown
- 2012-03-14 JP JP2013558425A patent/JP6105494B2/ja active Active
- 2012-03-14 RU RU2013145709A patent/RU2639472C2/ru active
- 2012-03-14 AU AU2012228273A patent/AU2012228273B2/en active Active
- 2012-03-14 PL PL12708358T patent/PL2686017T3/pl unknown
- 2012-03-14 US US14/003,871 patent/US9610245B2/en active Active
- 2012-03-14 HU HUE12708358A patent/HUE045467T2/hu unknown
- 2012-03-14 DK DK12708358.2T patent/DK2686017T3/da active
- 2012-03-14 BR BR112013023458A patent/BR112013023458B1/pt active IP Right Grant
- 2012-03-14 EP EP12708358.2A patent/EP2686017B1/en active Active
- 2012-03-14 SI SI201231672T patent/SI2686017T1/sl unknown
- 2012-03-14 WO PCT/EP2012/054498 patent/WO2012123515A1/en not_active Ceased
- 2012-03-14 ES ES12708358T patent/ES2736256T3/es active Active
- 2012-03-14 PT PT127083582T patent/PT2686017T/pt unknown
- 2012-03-14 CN CN201810366640.2A patent/CN108273065B/zh active Active
- 2012-03-14 CN CN201280013225.XA patent/CN103533962B/zh active Active
- 2012-03-14 CA CA2829164A patent/CA2829164C/en active Active
-
2017
- 2017-03-09 US US15/454,806 patent/US10154959B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103533962A (zh) | 2014-01-22 |
| WO2012123515A1 (en) | 2012-09-20 |
| JP2014509602A (ja) | 2014-04-21 |
| BR112013023458B1 (pt) | 2020-04-07 |
| SI2686017T1 (sl) | 2019-11-29 |
| CA2829164A1 (en) | 2012-09-20 |
| AU2012228273B2 (en) | 2015-08-20 |
| PL2686017T3 (pl) | 2020-03-31 |
| RU2013145709A (ru) | 2015-04-20 |
| EP2686017B1 (en) | 2019-07-03 |
| RU2639472C2 (ru) | 2017-12-21 |
| HUE045467T2 (hu) | 2020-01-28 |
| CN108273065B (zh) | 2020-07-31 |
| AU2012228273A1 (en) | 2013-05-02 |
| DK2686017T3 (da) | 2019-10-07 |
| JP6105494B2 (ja) | 2017-03-29 |
| EP2686017A1 (en) | 2014-01-22 |
| CA2829164C (en) | 2020-03-31 |
| PT2686017T (pt) | 2019-10-24 |
| CN103533962B (zh) | 2018-05-18 |
| US10154959B1 (en) | 2018-12-18 |
| CN108273065A (zh) | 2018-07-13 |
| US20130345150A1 (en) | 2013-12-26 |
| BR112013023458A2 (pt) | 2016-12-06 |
| US9610245B2 (en) | 2017-04-04 |
| ES2736256T3 (es) | 2019-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191711T1 (hr) | Oftalmološki pripravak | |
| ES2617683T3 (es) | Composiciones oftálmicas basadas en ácidos grasos Omega-3 y Omega-6 poliinsaturados | |
| Chime et al. | Characterization and Applications in Drug Delivery | |
| US20240350401A1 (en) | Topical delivery systems for active compounds | |
| ES2745084T3 (es) | Composiciones de alcanos semifluorados para uso en el tratamiento de la queraconjuntivitis seca | |
| JP6023181B2 (ja) | 爪に投与するための医薬組成物 | |
| Morsi et al. | Nanoemulsion as a novel ophthalmic delivery system for acetazolamide | |
| TWI434705B (zh) | 局部用組成物 | |
| JP7460707B2 (ja) | ポリアフロンおよびその眼瞼投与 | |
| RS55300B1 (sr) | Oftalmološka emulzija | |
| JP2008505177A (ja) | 目の障害および状態を治療するための組成物および方法 | |
| BR112015004997B1 (pt) | Composições oftálmicas contendo misturas de alcanos semifluorados | |
| Yılmaz Usta et al. | Evaluation of emulgel and nanostructured lipid carrier-based gel formulations for transdermal administration of ibuprofen: Characterization, mechanical properties, and ex-vivo skin permeation | |
| JP2018503670A5 (hr) | ||
| JP7240175B2 (ja) | 貯蔵安定性の眼用組成物 | |
| ES2539792T5 (es) | Vehículo en forma de una emulsión aceite-en-agua destinado principalmente a una utilización oftálmica o dermocosmética | |
| JP2022528854A (ja) | フルオロウラシル含有製剤 | |
| Vishwakarma et al. | Emulgel emergent systems: at a glance for topical drug delivery | |
| KR20140043562A (ko) | 무복계면 라타노프로스트 및 그 제조방법 | |
| CN105228631A (zh) | 包含透明质酸、毛蕊花糖苷和甘油磷酸肌醇的局部制剂 | |
| RU2414887C2 (ru) | Стерильный многофазный капельный глазной препарат | |
| CN112190504B (zh) | 一种含有玫瑰精油的长效液体凝胶及其制备方法和应用 | |
| JP7620703B2 (ja) | 非水性ゲル組成物 | |
| RU2777644C2 (ru) | Системы доставки для местного нанесения для активных веществ | |
| Hussain et al. | COMPREHENSIVE INSIGHTS INTO OLEOGELS |